Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Why Anorexic Patients Cling To Their Eating Disorder
Anorexic patients drastically reduce food intake and are often not capable of changing their behavior. This can lead to life-threatening weight loss. Using MRI technology, scientists at Heidelberg University Hospital have discovered for the first time processes in brain metabolism that explain this disturbed eating behavior.
generic viagra online
Iran Reports First Confirmed Case Of H1N1 Swine Flu
The Ministry of Health in Iran has reported the country"s first confirmed case of H1N1 swine flu, in a 16 year-old Iranian boy who lives in the US
News of the day
Pfizer To Present New Clinical Data Highlighting Customized Treatment Approaches For Difficult-To-Treat Cancers
Pfizer will present new data highlighting the company"s commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific patient populations in several advanced and difficult-to-treat cancers. These data will be presented later this month at the 45th Annual American Society of Clinical Oncology (ASCO) annual meeting in Orlando from May 29 to June 2.
Oncology

At American Diabetes Association Meeting, 2 Preclinical Abstracts Published By Versartis

Versartis, Inc., a new company developing novel biologics with enhanced properties for patients with metabolic diseases, published abstracts for preclinical data on its two product candidates, VRS-859 (exenatide-rPEG) and VRS-808 (glucagon-rPEG), at the American Diabetes Association Scientific Sessions annual meeting in New Orleans. Versartis, through a unique licensing agreement with Amunix, Inc., uses the proprietary Amunix recombinant PEGylation (rPEG) technology to extend the half life of established biologics. The Versartis compounds in development have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development. "With VRS-859, we have a product candidate that may become a "best in class" GLP-1 analog for the treatment of type 2 diabetes. This compound has similar preclinical efficacy to exenatide in animal models; and the pharmacokinetics in four species support monthly dosing in humans. VRS-859 can also be administered in a small volume with a small gauge needle," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "VRS-808 has the potential to prevent nocturnal hypoglycemia in type 1 diabetes, an unmet medical need," Dr. Cleland continued. "VRS-859 and VRS-808 did not have significant toxicology at very high doses in preclinical studies, including a lack of immunogenicity in all studies. We look forward to moving these products rapidly into human clinical trials to benefit diabetes patients." Abstracts: Exenatide: 1994-PO - "An Extended Half-life Exenatide Construct for Weekly Administration in the Treatment of Diabetes Mellitus" Glucagon: 2001-PO - "An Extended Half-life Glucagon Construct for the Prevention of Nocturnal Hypoglycemia" Debra Bannister Versartis, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009